MARKET

IPSC

IPSC

Century Therapeutics, Inc.
NASDAQ
1.670
-0.020
-1.18%
After Hours: 1.670 0 0.00% 19:30 09/25 EDT
OPEN
1.700
PREV CLOSE
1.690
HIGH
1.780
LOW
1.630
VOLUME
456.96K
TURNOVER
--
52 WEEK HIGH
3.040
52 WEEK LOW
0.4350
MARKET CAP
302.40M
P/E (TTM)
-1.8607
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IPSC last week (0914-0918)?
Weekly Report · 6d ago
Weekly Report: what happened at IPSC last week (0907-0911)?
Weekly Report · 09/14 09:16
Century Therapeutics Appoints IECURE CEO Joseph Truitt To Board As CNTY-813 Nears IND Filing
NASDAQ · 09/10 07:13
Century Therapeutics Adds Director, Advances Cell Therapy Pipeline
TipRanks · 09/09 20:31
Press Release: Century Therapeutics Appoints Joseph Truitt to Board of Directors
Dow Jones · 09/09 20:05
*Century Therapeutics Appoints Joseph Truitt to Bd of Directors
Dow Jones · 09/09 20:05
Weekly Report: what happened at IPSC last week (0831-0904)?
Weekly Report · 09/07 09:15
Weekly Report: what happened at IPSC last week (0824-0828)?
Weekly Report · 08/31 09:16
More
About IPSC
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.

Webull offers Century Therapeutics Inc stock information, including NASDAQ: IPSC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPSC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IPSC stock methods without spending real money on the virtual paper trading platform.